Stem cell mobilization for diamond blackfan anemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests whether a medication can help move your own blood stem cells from your bone marrow into your bloodstream, so they can be collected. This is a first step toward possibly using those cells in a future treatment for diamond blackfan anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have diamond blackfan anemia with a known gene change (mutation).
- You must be between 3 and 30 years old and weigh at least 22 pounds.
- You must have needed red blood cell transfusions regularly for at least 6 months.
- You must be enrolled in the diamond blackfan anemia registry of north america.
- You must be in reasonably good health (performance score 70% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This trial tests a specific type of bone marrow transplant for people with sickle cell disease (or certain other blood disorders) who have had serious complications despite standard care. It aims to see if removing the patient’s immune cells and using a matched donor’s cells can improve outcomes and reduce complications.
This study collects information from patients with Diamond Blackfan Anemia (DBA), a rare blood disorder that affects red blood cell production. By joining this registry, you help doctors better understand DBA and improve treatments for patients like you.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial is testing a new treatment called APR-2020 for children and young adults with a specific type of Diamond-Blackfan Anemia (caused by a change in the RPS19 gene). The goal is to see if this treatment is safe, tolerable, and can help reduce the need for blood transfusions.
This trial tests a machine that picks out healthy stem cells for a bone marrow transplant. It may help people with certain blood cancers or disorders get a transplant with fewer complications.
Hear when a new Diamond Blackfan Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.